Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at University of Texas, M.D. Anderson Cancer Center
February 24th, 2009
New research, 'Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity,' is the subject of a report. According to recent research from the United States, "The fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this cancer cell-specific receptor might serve as an ideal target for cancer therapy. To assess its potential as such a target, we constructed an oncolytic adenovirus with Retargeted Infectivity Via EGFR (Delta-24-RIVER) on the backbone of Delta-24." "This new oncolytic adenovirus...
Source: Cancer Weekly (2009-02-24)
|
